JSPR — Jasper Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Velan Capital Investment Management Lp Reports 10.2% Stake In Jasper Therapeutics Inc As Of Feb 16 - SEC Filing
Wells Fargo hikes Regeneron's PT, expects Dupixent to work in lung disease trial
Brief: Jasper Therapeutics Announces Positive Follow-Up Clinical Data From Investigator-Sponsored Study Of Briquilimab Conditioning In Sickle Cell Disease Patients
U.S. RESEARCH ROUNDUP-Evoqua Water Technologies, Taysha Gene Therapies, Veradigm
Brief: Jasper Therapeutics - On Jan 18, Received A Letter From Nasdaq Notifying Co That It Has Regained Full Compliance With Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP- First Republic Bank, Jasper Therapeutics, MSCI
U.S. STOCKS ON THE MOVE-Sutro Biopharma, NI, Estee Lauder
U.S. STOCKS ON THE MOVE-Jasper Therapeutics, Citigroup, Netflix
Jasper rises on promising early-stage data for lead product candidate
U.S. RESEARCH ROUNDUP- Boeing, Motorola Solutions, Tractor Supply
U.S. STOCKS ON THE MOVE-Oatly, Inari Medical, Netflix
U.S. STOCKS ON THE MOVE-Qualigen Therapeutics, Albertsons, ICON
U.S. STOCKS ON THE MOVE-Danaher, Bumble, Vyne Therapeutics
Brief: Jasper Therapeutics Announces Development Prioritization Of Briquilimab In Chronic Diseases
Jasper Therapeutics jumps on update for lead product candidate
Brief: Jasper Therapeutics Announces European Union Orphan Drug Designation For Briquilimab
Refile: BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Starbucks, ASLAN Pharma
U.S. STOCKS ON THE MOVE-Jasper Therapeutics, Blackstone, Mondelez
Jasper Therapeutics surges on positive data from blood disorder drug trial